APYX Quote, Financials, Valuation and Earnings

Accuray, Inc. has a net margin of -15.18% compared to Apyx Medical Corp.'s net margin of -13.47%. Apyx Medical Corp.'s return on equity of -146.08% beat Accuray, Inc.'s return on equity of -60.6%.

Apyx Medical Corp. has a consensus price target of $6.00, signalling upside risk potential of 56.25%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 396.85%. Given that Accuray, Inc. has higher upside potential than Apyx Medical Corp., analysts believe Accuray, Inc. is more attractive than Apyx Medical Corp..

Apyx Medical Corp. has a beta of 1.592, which suggesting that the stock is 59.181% more volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.124%.

Apyx Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical Corp. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.

Apyx Medical Corp. quarterly revenues are $12.9M, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. Apyx Medical Corp.'s net income of -$2M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, Apyx Medical Corp.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical Corp. is 3.22x versus 0.13x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nephros, Inc. has a net margin of -15.18% compared to Apyx Medical Corp.'s net margin of 7.07%. Apyx Medical Corp.'s return on equity of -146.08% beat Nephros, Inc.'s return on equity of 16.22%.

Apyx Medical Corp. has a consensus price target of $6.00, signalling upside risk potential of 56.25%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 62.5%. Given that Nephros, Inc. has higher upside potential than Apyx Medical Corp., analysts believe Nephros, Inc. is more attractive than Apyx Medical Corp..

Apyx Medical Corp. has a beta of 1.592, which suggesting that the stock is 59.181% more volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.397, suggesting its more volatile than the S&P 500 by 39.715%.

Apyx Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical Corp. pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.

Apyx Medical Corp. quarterly revenues are $12.9M, which are larger than Nephros, Inc. quarterly revenues of $4.8M. Apyx Medical Corp.'s net income of -$2M is lower than Nephros, Inc.'s net income of $337K. Notably, Apyx Medical Corp.'s price-to-earnings ratio is -- while Nephros, Inc.'s PE ratio is 28.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical Corp. is 3.22x versus 2.40x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Owlet, Inc. has a net margin of -15.18% compared to Apyx Medical Corp.'s net margin of 12.58%. Apyx Medical Corp.'s return on equity of -146.08% beat Owlet, Inc.'s return on equity of --.

Apyx Medical Corp. has a consensus price target of $6.00, signalling upside risk potential of 56.25%. On the other hand Owlet, Inc. has an analysts' consensus of $17.00 which suggests that it could grow by 57.85%. Given that Owlet, Inc. has higher upside potential than Apyx Medical Corp., analysts believe Owlet, Inc. is more attractive than Apyx Medical Corp..

Apyx Medical Corp. has a beta of 1.592, which suggesting that the stock is 59.181% more volatile than S&P 500. In comparison Owlet, Inc. has a beta of 1.713, suggesting its more volatile than the S&P 500 by 71.275%.

Apyx Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Owlet, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical Corp. pays -- of its earnings as a dividend. Owlet, Inc. pays out -- of its earnings as a dividend.

Apyx Medical Corp. quarterly revenues are $12.9M, which are smaller than Owlet, Inc. quarterly revenues of $32M. Apyx Medical Corp.'s net income of -$2M is lower than Owlet, Inc.'s net income of $4M. Notably, Apyx Medical Corp.'s price-to-earnings ratio is -- while Owlet, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical Corp. is 3.22x versus 1.80x for Owlet, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -15.18% compared to Apyx Medical Corp.'s net margin of -316.61%. Apyx Medical Corp.'s return on equity of -146.08% beat Plus Therapeutics, Inc.'s return on equity of --.

Apyx Medical Corp. has a consensus price target of $6.00, signalling upside risk potential of 56.25%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1861.48%. Given that Plus Therapeutics, Inc. has higher upside potential than Apyx Medical Corp., analysts believe Plus Therapeutics, Inc. is more attractive than Apyx Medical Corp..

Apyx Medical Corp. has a beta of 1.592, which suggesting that the stock is 59.181% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Apyx Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical Corp. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Apyx Medical Corp. quarterly revenues are $12.9M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Apyx Medical Corp.'s net income of -$2M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Apyx Medical Corp.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical Corp. is 3.22x versus 4.49x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.